Xtandi is named as an intervention in 17 current clinical trials in our Canada, Spain, South Korea, USA, Poland, Japan, Australia, UK, China, Germany, France, Brazil, Taiwan, Italy, Netherlands, Sweden, Czechia, Turkey, Israel, Switzerland, Belgium, Egypt, Austria, Norway, Denmark, India, Portugal, Mexico and Singapore registers. 8 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Pfizer (4). The most-studied condition is Prostate Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Prostate Cancer | 4 |
| Metastatic Castration-Resistant Prostate Cancer | 2 |
| Prostate Adenocarcinoma | 2 |
| Prostatic Neoplasms, Castration-Resistant | 2 |
| Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 2 |
| Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 2 |
| Metastatic Castration-resistant Prostate Cancer | 1 |
| Metastatic Castrate Resistant Prostate Cancer (mCRPC) | 1 |
| Metastatic Prostate Cancer | 1 |
| Metastatic Castration Sensitive Prostate Cancer (mCSPC) | 1 |
| Hormone Sensitive Prostate Cancer | 1 |
| Cancer of the Prostate | 1 |
| Metastatic Castration Resistant Prostate Cancer (mCRPC) | 1 |
| Small Cell Lung Cancer (SCLC) | 1 |
| Follicular Lymphoma (FL) | 1 |
| Metastatic Castration-resistant Prostate Cancer (mCRPC) | 1 |
| Castration-resistant Prostate Cancer Patients with Oligometastases | 1 |
| Castration-Resistant Prostate Cancer (CRPC) | 1 |
| Lead sponsor | Trials |
|---|---|
| Pfizer | 4 |
| AstraZeneca | 1 |
| Exelixis | 1 |
| Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic | 1 |
| Leiden University Medical Center | 1 |
| Karolinska Institutet | 1 |
| Institute of Cancer Research, United Kingdom | 1 |
| Medical Research Council | 1 |
| RTOG Foundation, Inc | 1 |
| British Columbia Cancer Agency | 1 |
| Sir Mortimer B. Davis - Jewish General Hospital | 1 |
| Hyundai Bioscience Co., Ltd | 1 |
| Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 1 |
| Beth Israel Deaconess Medical Center | 1 |
A trial with sites in more than one country appears in each of those registers.
17 current trials in our Canada, Spain, South Korea, USA, Poland, Japan, Australia, UK, China, Germany, France, Brazil, Taiwan, Italy, Netherlands, Sweden, Czechia, Turkey, Israel, Switzerland, Belgium, Egypt, Austria, Norway, Denmark, India, Portugal, Mexico and Singapore registers name Xtandi as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 8 of the 17 trials are recruiting: 3 with sites in Canada, 5 with sites in Spain, 4 with sites in South Korea, 4 with sites in USA, 4 with sites in Poland, 4 with sites in Japan, 3 with sites in Australia, 3 with sites in UK, 4 with sites in China, 3 with sites in Germany, 3 with sites in France, 3 with sites in Brazil, 3 with sites in Taiwan, 2 with sites in Italy, 3 with sites in Netherlands, 3 with sites in Sweden, 2 with sites in Czechia, 3 with sites in Turkey, 2 with sites in Israel, 3 with sites in Switzerland, 2 with sites in Belgium, 2 with sites in Egypt, 1 with sites in Austria, 1 with sites in Norway, 1 with sites in Denmark and 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Pfizer (4), AstraZeneca (1), Exelixis (1) and Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic (1), among 14 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Xtandi works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Xtandi works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Xtandi (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.